Novo Nordisk A/SNVONYSE
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank29
3Y CAGR-51.1%
5Y CAGR-14.0%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-51.1%/yr
vs +58.1%/yr prior
5Y CAGR
-14.0%/yr
Recent deceleration
Acceleration
-109.3pp
Decelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 4.12% |
| 2024 | 48.14% |
| 2023 | 34.91% |
| 2022 | 35.31% |
| 2021 | 14.94% |
| 2020 | 8.73% |
| 2019 | -3.95% |
| 2018 | 5.64% |
| 2017 | -3.77% |
| 2016 | 7.02% |